Aim: To characterize the biological profiles of MJ08, a novel selective CB 1 receptor antagonist. Methods: Radioligand binding assays were performed using rat brain and spleen membrane preparations. CB 1 and CB 2 receptor redistribution and intracellular Ca 2+ ([Ca 2+ ] i ) assays were performed with IN CELL Analyzer. Inverse agonism was studied using intracellular cAMP assays, and in guinea-pig ileum and mouse vas deferens smooth muscle preparations. In vivo pharmacologic profile was assessed in diet-induced obesity (DIO) mice. Results: In radioligand binding assay, MJ08 selectively antagonized CB 1 receptor (IC 50 =99.9 nmol/L). In EGFP-CB 1 _U2OS cells, its IC 50 value against CB 1 receptor activation was 30.23 nmol/L (SR141716A: 32.16 nmol/L). WIN 55,212-2 (1 μmol/L) increased [Ca 2+ ] i in the primary cultured hippocampal neuronal cells and decreased cAMP accumulation in CHO-hCB 1 cells. MJ08 (10 nmol/L-10 μmol/L) blocked both the WIN 55,212-2-induced effects. Furthermore, MJ08 reversed the inhibition of electrically evoked twitches of mouse vas deferens by WIN 55,212-2 (pA 2 =10.29±1.05). MJ08 and SR141716A both showed an inverse agonism activity by markedly promoting the contraction force and frequency of guinea pig ileum muscle. MJ08 significantly increased the cAMP level in CHO-hCB 1 cells with an EC 50 value of 78.6 nmol/L, which was lower than the EC 50 value for SR141716A (159.2 nmol/L). Besides the more potent pharmacological effects of cannabinoid CB 1 receptor antagonism in DIO mice, such as reducing food intake, decreasing body weight, and ameliorating dyslipidemia, MJ08 (10 mg/kg) unexpectedly raised the fasted blood glucose in vivo. Conclusion: MJ08 is a novel, potent and selective CB 1 receptor antagonist/inverse agonist with potent bioactive responses in vitro and in vivo that may be useful for disclosure the versatile nature of CB 1 receptors.
Introduction
Cannabinoid CB 1 receptors are widely expressed in both the central and peripheral nervous systems, and they display numerous physiological effects such as behavioral, neuroprotective, immunosuppressive, and metabolic functions [1] [2] [3] . In the past decade, the metabolic homeostasis regulated by the cannabinoid CB 1 receptor has been the focus of intensive studies. Striking advances were made in developing high affinity selective cannabinoid CB 1 receptor antagonists and/ or inverse agonists as therapeutic agents for obesity, diabetes and metabolic syndrome. Some selective antagonists of the cannabinoid CB 1 receptor have been developed and reached various stages of clinical trials. These new chemical entities also provided useful tools for understanding the sophisticated physiological mechanism of this receptor [4] [5] [6] . Among them, the most representative selective antagonist/inverse agonist of the cannabinoid CB 1 receptor is rimonabant (SR141716A). It was developed by Sanofi-Aventis and approved for treatment of obesity in Europe in June of 2006. Unfortunately, psychiatric side effects delayed its approval in the United States, which also led to subsequent market withdrawal of the drug in the European Union in late 2008. Hence, to circumvent the problems that have beset the current agents, some strategies such as developing non-brain penetrating and peripheral restrictive CB 1 receptor antagonists or focusing on allosteric modulation of CB 1 receptors are being used at present [7, 8] . Previously reported cannabinoid CB 1 receptor selective antagonists exhibited mainly two types of behavior [9, 10] . One type, expressed by SR141716A and Imidazole 24b, has effects in the opposite direction to those produced by the cannabinoid receptor agonists, ie, they are cannabinoid CB 1 receptor inverse agonists [11, 12] . The other type is expressed by the cannabinoid CB 1 receptor neutral antagonist, such as AM4113, with no intrinsic activity [13] . It was presumed that the inverse agonist and neutral antagonist may involve different signal transduction mechanisms. However, aside from their structural differences, the related pharmacological and toxicological effects produced by the different types of cannabinoid CB 1 receptor antagonists are still not completely known.
Novel drug candidates acting against cannabinoid CB 1 receptors, such as MJ08 and MJ15, were discovered in our laboratory through a series of in-vitro, ex-vivo, and in-vivo biological screenings and evaluations. Both compounds behaved as highly potent selective cannabinoid CB 1 receptor antagonists. Although they have similar molecular formulas, the substitution with piperidin-1-yl at the N atom of the pyrazol 3 site (N-pyridin-3-methyl for MJ15) characterizes MJ08 (patent No CN101062919A) with different receptor-binding characteristics and bioactivities [14] . MJ08 exhibits an inverse agonism activity even stronger than that of SR141716A in functional assays; however, it has a relatively lower affinity than SR141716A in radioligand competitive binding analysis. In addition to its significant weight loss effect, MJ08 increases fasting blood glucose in diet-induced obesity (DIO) mice. The in vitro and in vivo pharmacological profiles of MJ08 were described in this paper.
Materials and methods

Drugs and Chemicals
Forskolin, CP55, 940 (CB 1 /CB 2 agonist), WIN 55,212-2 (CB 1 / CB 2 agonist), and Fluo-3 were purchased from Sigma. [ 3 H]-SR141716A and [
3 H]-WIN 55,212-2 were purchased from Amersham. SR141716A and MJ08 were synthesized and prepared by the New Drug Design Center of Beijing Institute of Pharmacology and Toxicology. The purity and structure of these two compounds were confirmed by highperformance liquid chromatography, mass spectrometry and 1 H-nuclear magnetic resonance (NMR). The structure of MJ08 {[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl](piperidin-1-yl)methanone} is shown in Figure 1 .
Membrane preparations and radioligand competitive binding analysis
The cannabinoid CB 1 and CB 2 receptor membranes were prepared from rat brain and spleen, respectively, as reported in our previous paper, and stored at -80 °C until use [14] . Assay of cannabinoid receptor antagonism at the cellular level Thermo scientific CB 1 and CB 2 redistribution assays (Themo Fisher Bioimage ApS, Soeborg, Denmark) were used to analyze the antagonistic effects and the selectivity of MJ08 with SR141716A as the reference compound. The assay was performed as previously reported [14] . The cannabinoid CB 1 and CB 2 antagonist redistribution assay formats were specially designed cell models to screen agonists or antagonists of CB 1 and CB 2 receptors, respectively. The assay was validated with an average Z′=0.55±0.21 (CB 1 ) and Z′=0.34±0.1 (CB 2 ) and was suitable for both high content screening and profiling applications (Thermo scientific cannabinoid CB 1 and CB 2 redistribution assay specifications).
Before each experiment, the culture medium was changed to assay buffer [F12 culture medium containing 1 µmol/L Hoechst 33342 (Invitrogen, Oregon, USA)] and incubated at 37 °C for 20 min before different concentrations (10 nmol/L, 100 nmol/L, 1 µmol/L, and 10 µmol/L) of SR141716A or MJ08 combined with 1 µmol/L WIN 55,212-2 [the maximally active concentration on the EGFP-CB_U2OS cells (EGFP, enhanced green fluorescent protein)] was added. After further incubation at 37 °C for 2 h, the cells were imaged on the IN Cell Analyzer 1000 (20×objective), and the pictures were analyzed with the Granularity Analysis Module of IN Cell. DMSO (0.1%) was used as the vehicle control. The inhibition ratio of a test compound was expressed as percent inhibition of the internalization induced by the reference agonist WIN 55,212-2. The corresponding IC 50 values were calculated from the inhibition ratios. The results were obtained from three independent experiments performed in triplicate. 2+ assays were conducted in hippocampal neurons as previously described [14] . 2 , respectively) receptors were established in our previous work [14] . Functional antagonism of the cannabinoid CB 1 receptor agonist response was measured by incubating the recombinant cannabinoid CHO cells with various concentrations of test ligands and 200 μmol/L 3-isobutyl-1-methylxanthine (IBMX, phosphodiesterase inhibitor) in the assay buffer at room temperature for 30 min. The intrinsic inverse agonism was tested in the presence of 1 μmol/L forskolin in CHOhCB 1 and CHO-hCB 2 cells as above. Intracellular cAMP was assayed with the LANCE cAMP 384 kit (AD0262, PerkinElmer, CA, USA) according to the manufacturer's specifications. Briefly, cells were harvested with versene, washed with Hank's Balanced Salt Solutions (HBSS) and re-suspended in stimulation buffer at a concentration of 1.7×10 6 /mL. Six μL of the cell suspension (containing the Alexa-labeled antibodies) were added into one well of white OptiPlate-384, and then 6 μL of different compound dilutions was added. After incubation for 30 min at room temperature, 12 μL of detection mix was added and further incubated for 60 min. The fluorescence was read on EnVision Multilabel Plate Readers (PerkinElmer, CA, USA) with 475 nm excitation and 665 nm emission. The amounts of cAMP produced in the stimulated cells were determined according to the cAMP standard curves. In the inverse agonism assay, 10 μmol/L MJ08-enhanced, forskolin-stimulated cAMP production was used to define 100% efficacy, and the correspondent IC 50 values were calculated from the curve.
Tissue preparations and contraction studies
Male Kun-ming mice (25-30 g ) and guinea-pigs (350-400 g) from Laboratory Animal Center of Pharmaceutical University of Shenyang, China, were humanely killed by decapitation following CO 2 asphyxiation. The vas deferens and ileum were excised according to the method in the literature [15] [16] [17] and placed in Krebs' physiological salt solution [pH 7.4, composition (mmol/L): NaCl 119, KCl 4.69, KH 2 PO 4 1.18, glucose 11, NaHCO 3 25, CaCl 2 2.5, EDTA 0.026], gassed with 95% O 2 /5% CO 2 and maintained at 37 °C. Each vas deferens or ileum was mounted in a 30-mL organ bath and connected to an isometric transducer (RM6240CD, Chengdu, China). The vas deferens was subsequently equilibrated for 30 min and stimulated with trains of 10 pulses of 40 V for 0.5-ms duration at intervals of 50 ms. Contraction data were registered on a polygraph recorder before and after incubation with 10 -7 mol/L SR14716A, 10 -7 mol/L MJ08 or the vehicle (0.1% DMSO) for 30 min. The cannabinoid agonist WIN 55,212-2 was then added at 30-min intervals to construct an inhibitory cumulative concentrationresponse curve. The inhibition rate of the tested compounds was calculated with the following equation: (A n -A 0 )/A 0 ×100%, where A 0 and A n denote the twitch amplitude of the tested compounds before and after the administration of different concentrations of WIN 55,212-2, respectively. The pA 2 values were determined using the method of Arunlakshan and Schild, ie, pA 2 =log (E′/E-1)-logB, where E′ is the ED 50 of the agonist under the presence of the antagonist, E is the ED 50 of the agonist in the absence of the antagonist and B is the concentration of the antagonist.
Meanwhile, the specific effects of the test compounds on the contraction of the vas deferens smooth muscle and guineapig ileum were also observed. After equilibration for 30 min, the vas deferens was stimulated as described above, and a recording of the contraction amplitude was begun before administration of SR141716A or MJ08 for 30 min at ten-fold increments using 30-min intervals to construct a cumulative concentration-response curve. For the ileum, contraction data were recorded for 2 min before and after treatments, and cumulative concentration-response curves were generated. Male C57BL/6J mice (6 weeks old), maintained under controlled illumination (12/12-h light/dark cycle) and temperature (22±1 °C), were fed a high-fat diet (45% fat, 18% protein, 37% carbohydrate) for 16 weeks to obtain a DIO mouse model. Age-matched lean mice were used as normal controls. The DIO mice were randomly divided into three groups based on their initial body weights. SR141716A ( npg of the experimental period, the mice were fasted overnight, and blood samples were collected for the assessment of serum glucose, triglycerides (TG) and total cholesterol (TC) levels as previously described [18] .
Animals and treatment
Statistical analysis
All results are expressed as the mean±SD. For multiple comparisons, the statistical analysis was performed using one-way ANOVA followed by Tukey's multiple comparison tests with SPSS 11.5. P<0.05 was considered to be statistically significant.
Results
Selective interaction of MJ08 with the cannabinoid CB 1 receptor at the molecular level Figure 2 In contrast, both SR141716A and MJ08 showed very low affinity to the CB 2 receptor expressed in rat spleen preparations; even at a higher concentration (about 34% inhibition at 10 μmol/L for both compounds, n=6), they could not compete with the binding of [ 3 H]-WIN 55,212-2 to the CB 2 receptor. However, the cannabinoid CB 1 /CB 2 receptor agonist CP55,940 could antagonize this effect under the same conditions, with more than 90% inhibition to the CB 2 receptor at 100 nmol/L (data not shown). These results indicate that MJ08 is a selective cannabinoid CB 1 (not CB 2 ) ligand but that it has relatively lower affinity than SR141716A at an in vitro molecular level.
MJ08 antagonized the activation of the cannabinoid CB 1 receptor at the cellular level As a G i/s -coupled G-protein-coupled receptor (GPCR), the cannabinoid receptor is rapidly internalized following agonist binding and receptor activation [19] . Recombinant U2OS cells stably express human cannabinoid CB 1 or CB 2 receptors fused to the N-terminus of EGFP. The cannabinoid CB 1 or CB 2 receptor internalization assay is available for the screening of agonists or antagonists of the cannabinoid CB 1 and CB 2 receptors. . Figure 3A shows that 1 μmol/L CB 1 /CB 2 receptor agonist WIN 55,212-2 markedly induced the internalization of the membrane-localized CB 1 -EGFP fusion protein to the endosomes; the agonistic potency was 2.59 times that of the vehicle control. However, when co-administered with MJ08, it dosedependently antagonized the internalization of the CB 1 -EGFP fusion protein, and the IC 50 calculated from the concentrationresponse curve was 30.23±6.41 nmol/L, which was comparable to the value of SR141716A (32.16±6.72 nmol/L) in the same experiment ( Figure 3B ). However, both SR141716A and MJ08 exhibited weak antagonism towards the cannabinoid CB 2 receptor activation and internalization induced by WIN 55,212-2 in EGFP-CB 2 _U2OS cells, with only approximately 25% to 35% inhibition by 10 μmol/L of MJ08 or SR141716A (data not shown). Therefore, MJ08 is macroscopically demonstrated to be equally potent and selective as a CB 1 receptor antagonist as SR141716A in the cellular assay. 
Antagonism on intracellular cAMP and inverse agonism of MJ08
The effect of MJ08 on the agonist-mediated decrease of cAMP level in CHO cells expressing human cannabinoid CB 1 receptor was examined. Like SR141716A, MJ08 (0.1 and 1 μmol/L) also significantly and dose-dependently reversed the WIN 55,212-2-induced inhibition of forskolin-stimulated cAMP accumulation, and intracellular cAMP contents at higher doses even exceeded that induced by forskolin alone; this suggests that MJ08 may also possess the inverse agonism property (Figure 5A ). Neutral antagonists and inverse agonists can be well differentiated by the intracellular cAMP assay when the agonist is absent. Therefore, to further verify its functional inverse agonism, MJ08 was tested by the cAMP assays in both CHOhCB 1 and CHO-hCB 2 cells. Figure 5B showed that 1 nmol/L of MJ08 can further increase cAMP levels in CHO-hCB 1 cells in the presence of 1 μmol/L forskolin, and the four-fold increase of the E max (maximal effect) was obtained at 10 μmol/L with the EC 50 of 78.6 nmol/L. However, an antagonizing effect of SR141716A was observed at 1 nmol/L under the same conditions. Inverse agonism was displayed above 10 nmol/L, and the E max value was significantly lower than that of MJ08 (P<0.05), which corresponds to that of MJ08 at 1 μmol/L. The EC 50 in this assay was 159.2 nmol/L, about two-fold that of MJ08. However, MJ08 and SR141716A did not influence intracellular cAMP in CHO-hCB 2 cells, even at 10 μmol/L. These data indicate that MJ08 possesses more potent intrinsic inverse agonistic activity to CB 1 receptors than SR141716A in the absence of the receptor agonist.
The effects of MJ08 on the contraction of guinea pig ileum and mouse vas deferens smooth muscle At concentrations of 10 -6 and 10 -5 mol/L, SR141716A markedly increased the contraction intensity of guinea pig ileum smooth muscle, but its potency tended to decrease in a timedependent manner ( Figure 6A ). The contraction frequency was only significantly increased at 10 -5 mol/L at 60 and 120 s after the administration ( Figure 6C ). MJ08 demonstrated a similar promotion effect. It remarkably increased the contraction force and frequency. However, a more significant effect was observed on frequency, which was strikingly enhanced by MJ08 and without attenuation over time, even at 10 -9 mol/L at 60 s ( Figure 6B, 6D) .
The electrically-stimulated vas deferens bioassay was reported to be a preferable approach for the determination of the antagonist potency [17] . Without pretreatment with the antagonist, the cannabinoid CB 1 /CB 2 receptor agonist WIN 55,212-2 elicited a concentration-dependent inhibition of the twitches of mouse vas deferens (IC 50 =0.44 nmol/L), and a nearly completed inhibition appeared at 10 -6 mol/L ( Figure 7A  and B) . At 10 -7 mol/L, both SR141716A and MJ08 significantly antagonized the inhibitory effect of WIN 55,212-2 (P<0.01 for both) and induced dextral displacements of the agonist's doseresponsive curve with IC 50 values of 0.206 and 3.31 μmol/L, respectively ( Figure 7A ). The competitive interaction between the antagonist and agonist signified that SR141716A and Figure 7B ). Furthermore, MJ08 and SR141716A both had trends towards promoting the electrically-evoked twitches of the mouse vas deferens even at a concentration of 1 nmol/L in absence of the agonist, although without apparent dose-response relationships (data not shown). These results indicate that MJ08 is not only a selective and competitive CB 1 receptor antagonist but also a cannabinoid CB 1 receptor 
Effect of MJ08 in DIO mice
Adverse effects on animal behavior or obvious signs of toxicity were not observed at any point in the experiment for any treatment group. The body weight of DIO mice was significantly higher than that of normal mice (32.02±0.83 g vs 24.3±0.29 g, P<0.01) at the beginning of the experiment. Sequential monitoring showed that both SR141716A and MJ08 decreased the body weight of the DIO mice throughout the experiment. On average, the body weight of MJ08-treated mice was relatively lower than that of SR141716A-treated mice during the first 25 d of treatment ( Figure 8A ). The impact of food intake was similar between the two testing compounds, which was reduced only in the first 10 d of administration and then relapsed to the consumption amount of the model group ( Figure 8B ). Meanwhile, both SR141716A and MJ08 dramatically decreased the hypertriglyceridemia (P<0.05) and the intra-abdominal adipose tissue (P<0.05) in DIO mice (Table  1) . However, different from SR141716A, MJ08 also markedly lowered serum TC levels (P<0.05). Unexpectedly, the fasting blood glucose of the DIO mice was significantly increased by MJ08 after 35 d of treatment (P<0.01), yet it was decreased by SR141716A. However, the increased fasting blood glucose soon recovered to normal once MJ08 was withdrawn (the FBG were 5.04±1.09 mmol/L and 4.57±0.91 mmol/L at 5 and 10 d after discontinuation, respectively).
Discussion
As a new chemical entity targeting the cannabinoid CB 1 receptor, the pharmacological properties of MJ08 were evaluated in various in vitro and in vivo experimental systems in the present study. MJ08 exhibited selective and potent antagonism to the cannabinoid CB 1 receptor. Although in vitro competitive binding analysis revealed that its affinity was lower than that of SR141716A at the molecular level, the cellular cannabinoid receptor activation and transposition assay, [Ca 2+ ] i and cAMP measurements in mammalian cells functionally demonstrated the equivalent efficiency of MJ08 in selectively antagonizing the cannabinoid CB 1 receptor compared with SR141716A. Furthermore, more potent or equivalent cannabinoid CB 1 recep- Receptor competitive binding analysis is a classical method for the evaluation of binding characteristics of ligands. Rat cerebellum and spleen (CB 1 and CB 2 receptor-rich tissues, respectively) membrane preparations were used here to analyze the receptor binding activity and characteristics of MJ08. The radioligand displacement curves showed that, similar to the well-known cannabinoid CB 1 receptor selective antagonist SR141716A, MJ08 dose dependently displaced [ 3 H]-SR141716A binding to rat cerebellum membranes, and its selectivity to the CB 1 receptor against the CB 2 receptor was more than 100-fold. However, the binding affinity of MJ08 to the CB 1 receptor was about 500-1000 times less potent than that of SR141716A. It was noted that the slope of the displacement curve was steeper for SR141716A than MJ08, SR141716A exhibited a sharp competitive effect from 10 -11 to 10 -9 mol/L, but MJ08 gradually inhibited [ mol/L. This result indicates that the binding mode of MJ08 is somewhat different from that of SR141716A. MJ08 showed more potent affinity to the CB 1 receptor at a lower concentration in the molecular test. Recently, functional assays of receptor activation in living cells were widely used in screening and in the evaluation of novel ligands for receptors. Compared with molecular-level assays, living cell assays reflect both receptor binding and the functional activity of a ligand. In this study, the CB 1 /CB 2 redistribution assay (commercial EGFP-CB 1 /CB 2 _U2OS cell model, specially designed for screening of agonists or antagonists of cannabinoid CB 1 /CB 2 receptor with High Content Assay) was used. Both MJ08 and SR141716A antagonized the internalization of the membrane-located CB 1 -EGFP fusion protein induced by the agonist (WIN 55,212-2) without significant impact to WIN 55,212-2-induced internalization of the membrane-located CB 2 -EGFP fusion protein; this signified that they selectively antagonized the cannabinoid CB 1 receptor activation in the cellular model. Moreover, in contrast to the receptor binding test at the molecular level, MJ08 displayed an equivalent antagonistic effect to SR141716A in the living cell assay suggesting that MJ08 may be more suitable for binding to CB 1 receptor in living cells.
Intracellular Ca 2+ and adenylyl cyclase are considered to be important signaling molecules of cannabinoid CB 1 receptors [20] [21] [22] . To confirm the functional antagonistic activities of MJ08 toward the cannabinoid CB 1 [20] . In our experiment, similar to SR141716A and other reported antagonists [23, 24] ] i and cAMP assays demonstrated that MJ08 acts as a cannabinoid CB 1 receptor antagonist of second messenger signaling in mammalian cells with similar efficacy to SR141716A. Additionally, both SR141716A and MJ08 significantly antagonized the inhibition by WIN 55,212-2 of the contraction of mouse vas deferens smooth muscle with electrical stimulation. The relatively higher pA 2 value of MJ08 than SR141716A in this assay indicates its stronger or comparable antagonism. Therefore, the above results suggest that MJ08 is a potent and highly selective cannabinoid CB 1 receptor antagonist.
On the other hand, MJ08 also displayed inverse agonist properties, ie, inhibiting CB 1 receptor activity in the absence of an agonist, which includes directly increasing cAMP accumulation in CHO-hCB 1 cells and promoting contractions of isolated preparations of guinea pig ileum and mouse vas deferens. In CHO-hCB 1 cells, MJ08 not only enhanced cAMP accumulation in the presence of forskolin (its efficacy was about 5 to 10 times of SR141716A) but also markedly evoked the increase of intracellular cAMP in the absence of forskolin at higher concentrations. The efficacy of 1 μmol/L of MJ08 also corresponds to the efficacy of 10 μmol/L of SR141716A (data not shown). This result indicates that MJ08 is a more potent inverse agonist of the cannabinoid CB 1 receptor than SR141716A. SR141716A has been shown to enhance the contraction force of guinea pig ileum smooth muscle in isolated guinea pig ileum tests, but we found that it displayed a time-dependent decreasing trend, with the maximum effect at 30 s. The contraction frequency was increased 1.16 times by 10 -5 mol/L SR141716A at 60 s, whereas MJ08 significantly enhanced both the contraction force and frequency under the same conditions without attenuation with time. The contraction frequency was significantly increased by MJ08 even at 10 -9 mol/L at 60 s and reached to 1.24 times with 10 -5 mol/L MJ08. In the isolated mouse vas deferens experiment, similar to known inverse agonists, SR141716A or and MJ08 also both promoted the electricallyevoked contractions of the mouse vas deferens at concentrations ranging from 10 -10 to 10 -6 mol/L, although the contraction amplitude was only slightly increased. This phenomenon corresponded with the point that the inverse agonist exhibited greater potency in producing opposing effects induced by the cannabinoid CB 1 receptor agonists [9] . As MJ08 did not interact directly with the muscarinic receptor or adrenergic receptor α (data not shown), the mechanisms by which MJ08 promotes muscle contraction and the electrically-evoked contractions of the mouse vas deferens are likely to be cannabinoid CB 1 receptor mediated rather than through non-specific interactions with other receptors. Therefore, MJ08 is a selective antagonist and inverse agonist of the cannabinoid CB 1 receptor.
Previously, an increasing body of evidence has demonstrated the roles of the endogenous cannabinoid system (ECs), including CB 1 receptor, endocannabinoids, and related metabolic enzymes, in the regulation of food consumption and body weight in animals and humans [25, 26] . Hyperphagic effects are closely related to the hyperactivity of the ECs, and thus the endocannabinoid system had been a valuable therapeutic target for obesity [27, 28] . Correspondingly, the cannabinoid CB 1 receptor antagonist had been shown to attenuate food intake and increase body energy expenditure in DIO mice and genetic obese animals [26, 29, 30] . Thus, in the present study, high-fat diet-induced obese mice were used to evaluate the in vivo pharmacodynamic effects of MJ08. Compared with SR141716A, chronic treatment with MJ08 displayed a higher efficacy in inducing weight loss (although without statistical difference), correcting dyslipidemia, and in lowering retroperitoneal adipose tissue in DIO mice. This effect suggests that MJ08 is an orally active cannabinoid CB 1 receptor antagonist. Additionally, a significant increase in FBG in DIO mice by MJ08 was surprisingly found after 40 d of treatment; however, the FBG values returned to normal soon after compound withdrawal. Similarly, during the preparation of our manuscript, another CB 1 receptor inverse agonist AM251 was also reported to increase the serum glucose level in 24-h fasted obese rats, but the author attributed it to heavy insulin resistance produced by hypercaloric diets [31] . However, this conclusion seems inappropriate because the serum insulin and glucose levels of the obese rats were both lower than that of the standard diet rats; the levels of the other two hormones (adiponectin and leptin) relating to glucose homeostasis were also comparable to the non-obese rats in their study [31] . Here, we considered two reasons may be responsible for this FBG increasing effect of a cannabinoid CB 1 receptor antagonist/ inverse agonist MJ08: first, it may be related to the activation of the sympathoadrenal system and the release of noradrenaline, which had been recently demonstrated in the dietinduced obese rats by Molhoj et al [32] ; and secondly, MJ08 itself markedly increased intracellular cAMP, which may have promoted gluconeogenesis and/or glycogenolysis via increasing phosphorylation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphate (G6P), respectively. Therefore, the more potent inverse agonistic characteristic of MJ08 may be partially related to this FBG increasing effect, although the detailed mechanisms still need further study. However, if this is a category response of some CB 1 receptor inverse agonists can't be completely excluded.
Additionally, it was also observed that the bioactivities of MJ08 became more potent as the experimental system advanced from the in vitro molecular level to the cellular level and then to the in vivo experiments; a significant enhancement was particularly seen between the molecular and cellular systems. First, we think that the incomplete, identical binding modes of MJ08 and SR141716A and the minute conformational change of the cannabinoid CB 1 receptor in cell membrane preparations and living cells may be responsible for the phenomenon. When considering the cannabinoid CB 1 receptor to be a well-defined but dynamic receptor protein, changes in the receptor steric conformation under different circumstances will likely affect its response to exogenous ligands. Secondly, the complex pharmacological regulations depend on the particular profile of the used ligand; the minute difference in structure of MJ08 may be key because the compound's conformation or conformational freedom is crucial for the receptor's affinity, selectivity, and efficacy [33] . Different small-molecule antagonists and inverse agonists bind in very different modes into the funnel of the main ligand-binding pocket GPCRs. In fact, MJ08 has a different amide in the 3 site of the pyrazole compared with SR141716A; when calculated with ChemOffice 2008, the LogP of MJ08 (7.04) is higher than that of SR141716A (6.28) . This indicates that SR141716A is more hydrophilic than MJ08 and may thus display higher affinity at the in vitro molecular level, which is also confirmed by their different behaviors in the thin-layer chromatography assay. Certainly, the involved mechanisms need to be studied in further detail.
In conclusion, MJ08 is a structurally novel, potent and selective cannabinoid CB 1 receptor antagonist with many specialized pharmacologic effects on different experimental systems. It exhibits potent inverse agonism and in vivo bioactivity. MJ08 may be used as a novel pharmacological tool to characterize the versatile nature and complexity of the cannabinoid signaling pathway.
